New Antiarrhythmic Drugs for the Treatment of Atrial Fibrillation

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Herz Kardiovaskuläre Erkrankungen

• Publication date

  2008-12-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s00059-008-3151-zPMID 19137246
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rhythm control versus rate control for atrial fibrillation and heart failure.

  2008cited by this paper
• Risk Stratification Using T‐Wave Alternans: More Questions Waiting to be Answered

  2008cited by this paper
• Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation: A Phase 3, Randomized, Placebo-Controlled Trial

  2008cited by this paper
• Atrial-selective approaches for the treatment of atrial fibrillation.

  2008cited by this paper
• Increased mortality after dronedarone therapy for severe heart failure.

  2008cited by this paper
• Characterization of Human Cardiac Kv1.5 Inhibition by the Novel Atrial-selective Antiarrhythmic Compound AVE1231

  2008cited by this paper
• Can inhibition of IKur promote atrial fibrillation?

  2008cited by this paper
• Rationale and Design of ATHENA: A Placebo‐Controlled, Double‐Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg Bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in PatiENts with Atrial Fibrillation/Atrial Flutter

  2007cited by this paper
• Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study.

  2007cited by this paper
• Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.

  2007influential reference
• Evidence-based cardiology Dronedaron – oczekiwany następca amiodaronu? Commentary to the article:Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357: 987-99.

  2007cited by this paper
• Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent

  2007cited by this paper
• Dronedarone: An Emerging Agent with Rhythm‐ and Rate‐Controlling Effects

  2006cited by this paper
• Activation of Inward Rectifier Potassium Channels Accelerates Atrial Fibrillation in Humans: Evidence for a Reentrant Mechanism

  2006cited by this paper
• Innovative approaches to anti-arrhythmic drug therapy

  2006cited by this paper
• Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation.

  2006cited by this paper
• RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents.

  2006cited by this paper
• The Mechanism of Atrial Antiarrhythmic Action of RSD1235

  2005cited by this paper
• Mechanisms of Atrial Fibrillation Termination by Pure Sodium Channel Blockade in an Ionically-Realistic Mathematical Model

  2005cited by this paper
• Recent progress in the epidemiology of atrial fibrillation

  2005cited by this paper
• Role of IKur in Controlling Action Potential Shape and Contractility in the Human Atrium: Influence of Chronic Atrial Fibrillation

  2004cited by this paper
• A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.

  2004cited by this paper
• Characterization of a hyperpolarization‐activated time‐dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium

  2004cited by this paper
• Dronedarone for prevention of atrial fibrillation: a dose-ranging study.

  2003cited by this paper
• A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation

  2003cited by this paper
• Rate control versus electrical cardioversion for atrial fibrillation: A randomised comparison of two treatment strategies concerning morbidity, mortality, quality of life and cost-benefit - the RACE study design.

  2002cited by this paper
• Chronic and Acute Effects of Dronedarone on the Action Potential of Rabbit Atrial Muscle Preparations: Comparison With Amiodarone

  2002cited by this paper
• A comparison of rate control and rhythm control in patients with atrial fibrillation.

  2002cited by this paper
• A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

  2002cited by this paper
• The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation.

  2001cited by this paper
• Molecular Basis of Downregulation of G-Protein–Coupled Inward Rectifying K+ Current (IK,ACh) in Chronic Human Atrial Fibrillation: Decrease in GIRK4 mRNA Correlates With Reduced IK,ACh and Muscarinic Receptor–Mediated Shortening of Action Potentials

  2001cited by this paper
• Distribution of the Muscarinic K+ Channel Proteins Kir3.1 and Kir3.4 in the Ventricle, Atrium, and Sinoatrial Node of Heart

  2001cited by this paper
• Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat.

  2000cited by this paper
• Amiodarone to prevent recurrence of atrial fibrillation.

  2000cited by this paper
• Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial.

  2000cited by this paper
• Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.

  2000cited by this paper
• Cardiac Ultrarapid Delayed Rectifiers

  1999cited by this paper
• Cardiac ultrarapid delayed rectifiers: a novel potassium current family o f functional similarity and molecular diversity.

  1999cited by this paper
• Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart : comparison with amiodarone.

  1999cited by this paper
• Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.

  1998cited by this paper
• Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation.

  1997cited by this paper
• Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

  1995cited by this paper
• Proarrhythmia with Class III Antiarrhythmic Drugs: Definition, Electrophysiologic Mechanisms, Incidence, Predisposing Factors, and Clinical Implications

  1995cited by this paper
• Localization of the Kv1.5 K+ channel protein in explanted cardiac tissue.

  1995cited by this paper

• Voltage-gated sodium channels in excitable cells as drug targets

  2025cites this paper
• A Q-transform-based deep learning model for the classification of atrial fibrillation types

  2024cites this paper
• Handbook of Ion Channels

  2023cites this paper
• Tic-Tac: A Translational Approach in Mechanisms Associated with Irregular Heartbeat and Sinus Rhythm Restoration in Atrial Fibrillation Patients

  2023cites this paper
• Cardiomyocyte electrophysiology and its modulation: current views and future prospects

  2023cites this paper
• Dual effects of the small-conductance Ca2+-activated K+ current on human atrial electrophysiology and Ca2+-driven arrhythmogenesis: an in silico study

  2023cites this paper
• Improved Atrial Differentiation of Human Pluripotent Stem Cells by Activation of Retinoic Acid Receptor Alpha (RARα)

  2022cites this paper
• Recent advances in gene therapy for atrial fibrillation

  2021cites this paper
• The crosstalk between cardiomyocyte calcium and inflammasome signaling pathways in atrial fibrillation

  2021cites this paper
• Safety and Efficacy of Ibutilide for Acute Pharmacological Cardioversion of Rheumatic Atrial Fibrillation

  2021cites this paper
• Components and Pharmacodynamical Mechanism of Yinfupian Based on Liquid Chromatography-Mass Spectrometry and Proteomics Analyses

  2021cites this paper
• Mechanisms of atrial fibrillation

  2019cites this paper
• Production of hiPSC-derived atrial cardiomyocytes to study the contribution of the KCNN3 variants to lone atrial fibrillation

  2019cites this paper
• Antiarrhythmic Properties of Ranolazine: Inhibition of Atrial Fibrillation Associated TASK-1 Potassium Channels

  2019cites this paper
• Emerging pharmacotherapies for the treatment of atrial fibrillation

  2018cites this paper
• University of Birmingham German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper

  2018cites this paper
• Establishing a Single-cell and High-throughput Phenotypical Platform to Identify Novel Arrhythmia-Causing Genes

  2018cites this paper
• Induction of atrial endothelial senescence by angiotensin II and thrombin : role of oxidative stress and characterization of pro-thrombotic, pro-adhesive, proteolytic and pro-fibrotic phenotype

  2018cites this paper
• Study the Effects of Vernakalant on Ischemic-Reperfusion Dysrhythmias in Experimental Animals in Comparison with Amiodarone

  2018influential citation
• Concise Reviews: Criteria for Chamber-Specific Categorization of Human Cardiac Myocytes Derived from Pluripotent Stem Cells

  2017cites this paper
• Omega-3 Index and Anti-Arrhythmic Potential of Omega-3 PUFAs

  2017cites this paper
• Resultados de un primer procedimiento de crioablación como tratamiento de la fibrilación auricular paroxística

  2017cites this paper
• Biological influence of extracts of cryopreserved fragments of piglets’ heart and skin

  2017cites this paper
• Cardiac troponin-I as a predictor of mortality in patients with first episode acute atrial fibrillation

  2017cites this paper
• Laser catheter ablation of long- lasting persistent atrial fibrillation: Longterm results.

  2017cites this paper
• Feasibility of selection of antiarrhythmic drug treatment on the basis of arrhythmogenic mechanism — Relevance of electrical restitution, wavebreak and rotors

  2017cites this paper
• Structural basis for the antiarrhythmic blockade of a potassium channel with a small molecule

  2017cites this paper
• Concise Review: Criteria for Chamber‐Specific Categorization of Human Cardiac Myocytes Derived from Pluripotent Stem Cells

  2017cites this paper
• Investigational antiarrhythmic agents: promising drugs in early clinical development

  2017cites this paper
• Patch-Clamp Recording from Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Improving Action Potential Characteristics through Dynamic Clamp

  2017cites this paper
• Deciphering the fundamental mechanisms of atrial fibrillation: a quest for over a century.

  2016influential citation
• The QT Interval as a Noninvasive Marker of Atrial Refractoriness

  2016cites this paper
• Acupuncture Prevents the Atrial Fibrillation through Improving Remodeling of Atrial Appendage in Rats

  2016cites this paper
• Atrial Heterogeneity Generates Re-entrant Substrate during Atrial Fibrillation and Anti-arrhythmic Drug Action: Mechanistic Insights from Canine Atrial Models

  2016influential citation
• High fat diet induced alterations of atrial electrical activities in mice.

  2016cites this paper
• Keeping up the balance: role of HDACs in cardiac proteostasis and therapeutic implications for atrial fibrillation.

  2016cites this paper
• Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation

  2016cites this paper
• The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis.

  2016cites this paper
• Novel ion channel targets in atrial fibrillation

  2016cites this paper
• Recent Advances in the Pharmacological Management of Atrial Fibrillation

  2016cites this paper
• Up-regulation of miR-31 in human atrial fibrillation begets the arrhythmia by depleting dystrophin and neuronal nitric oxide synthase

  2016cites this paper
• Resveratrol and derivatives for the treatment of atrial fibrillation

  2015cites this paper
• Involvement of Class I and Class IIa HDACs in the derailment of gene expression in Atrial Fibrillation

  2015cites this paper
• Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology

  2015influential citation
• Antiarrhythmic principle of SK channel inhibition in atrial fibrillation.

  2015cites this paper
• Targeting proteostasis in atrial fibrillation

  2015cites this paper
• Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.

  2015cites this paper
• Effect of TGF-β1 on the expression of collagen in rat atrial and ventricular fibroblasts

  2015cites this paper
• Effects of Wild-Type and Mutant Forms of Atrial Natriuretic Peptide on Atrial Electrophysiology and Arrhythmogenesis

  2015cites this paper
• Frontiers in Non-invasive Cardiac Mapping: Rotors in Atrial Fibrillation-Body Surface Frequency-Phase Mapping.

  2015cites this paper
• Role of Nuclear Angiotensin-II Receptor Mediated Signalling in Cardiovascular Remodelling

  2015cites this paper
• Alternating membrane potential/calcium interplay underlies repetitive focal activity in a genetic model of calcium‐dependent atrial arrhythmias

  2015cites this paper
• Vernakalant for the Conversion of Atrial Fibrillation: The New Kid On the Block?

  2014cites this paper
• Evolution and pharmacological modulation of the arrhythmogenic wave dynamics in canine pulmonary vein model

  2014cites this paper
• Pharmacometrics in Cardiovascular Safety

  2014cites this paper
• Inefficacy of a Highly Selective T‐Type Calcium Channel Blocker in Preventing Atrial Fibrillation Related Remodeling

  2014cites this paper
• Ryanodine Receptor–Mediated Calcium Leak Drives Progressive Development of an Atrial Fibrillation Substrate in a Transgenic Mouse Model

  2014influential citation
• Dronedarone: "real-world" data vis-à-vis data from randomized clinical trials.

  2014cites this paper
• Management of Atrial Fibrillation in Critically Ill Patients

  2014cites this paper
• Keep your heart in shape: molecular chaperone networks for treating heart disease.

  2014cites this paper
• Antiarrhythmic strategies in patients with atrial fibrillation managed by cardiologists and internists: Antithrombotic Agents in Atrial Fibrillation (ATA-AF) survey

  2014cites this paper
• Cardiac safety assays.

  2014cites this paper
• Fibrillation Initiation , Maintenance , and Progression

  2014cites this paper
• Impaired local regulation of ryanodine receptor type 2 by protein phosphatase 1 promotes atrial fibrillation.

  2014influential citation
• Allitridin Reduces IKr Current by Disrupting the Trafficking of Human Ether-à-Go-Go-Related Gene Channels

  2014cites this paper
• Cilostazol ameliorates atrial ionic remodeling in long-term rapid atrial pacing dogs

  2014cites this paper
• Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation

  2014cites this paper
• Cellular and Molecular Electrophysiology of Atrial Fibrillation Initiation, Maintenance, and Progression

  2014cites this paper
• Loss of proteostasis as a substrate for atrial fibrillation

  2014cites this paper
• Aortic coarctation: late complications and treatment strategies

  2014cites this paper
• Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine

  2013influential citation
• Mechanisms of hepatocellular toxicity associated with dronedarone--a comparison to amiodarone.

  2013cites this paper
• Rotor Termination Is Critically Dependent on Kinetic Properties of I Kur Inhibitors in an In Silico Model of Chronic Atrial Fibrillation

  2013cites this paper
• Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update

  2013influential citation
• Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study.

  2013influential citation
• Pleiotropic Effects of Antiarrhythmic Agents: Dronedarone in the Treatment of Atrial Fibrillation

  2013cites this paper
• Atrial fibrillation in heart failure: The sword of Damocles revisited.

  2013cites this paper
• N‐3 Polyunsaturated Fatty Acids to Prevent Atrial Fibrillation: Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials

  2013cites this paper
• Atrial arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia – is there a mechanistic link between sarcoplasmic reticulum Ca2+ leak and re‐entry?

  2013cites this paper
• Novel molecular targets for atrial fibrillation therapy

  2012cites this paper
• Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial.

  2012cites this paper
• Translational Research in Atrial Fibrillation: A Quest for Mechanistically Based Diagnosis and Therapy

  2012cites this paper
• Systematic Review and Meta-analysis of the Efficacy of Cardioversion by Vernakalant and Comparators in Patients with Atrial Fibrillation

  2012cites this paper
• Dronedarone reduces arterial thrombus formation

  2012cites this paper
• Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing

  2012cites this paper
• Polyunsaturated Fatty Acids Modify the Gating of Kv Channels

  2012cites this paper
• Novel Therapies for Treating Atrial Fibrillation

  2012cites this paper
• Efficacy and Safety of Vernakalant in Recent‐Onset Atrial Fibrillation After the European Medicines Agency Approval: Systematic Review and Meta‐Analysis

  2012cites this paper
• Risk Stratification in Atrial Fibrillation Patients - A Review Focused on Mortality.

  2012cites this paper
• Loss of Proteostatic Control as a Substrate for Atrial Fibrillation: A Novel Target for Upstream Therapy by Heat Shock Proteins

  2012cites this paper
• Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels

  2012cites this paper
• Dronedarone for atrial fibrillation therapy

  2011cites this paper
• Canadian Cardiovascular Society atrial fibrillation guidelines 2010: implementing GRADE and achieving consensus.

  2011cites this paper
• Elevated Free Fatty Acid is Associated with Cardioembolic Stroke Subtype

  2011cites this paper
• Pharmacological Management of Atrial Fibrillation: One, None, One Hundred Thousand

  2011cites this paper
• HSPB1, HSPB6, HSPB7 and HSPB8 Protect against RhoA GTPase-Induced Remodeling in Tachypaced Atrial Myocytes

  2011cites this paper
• The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications.

  2011cites this paper
• Update on the Management of Atrial Fibrillation: Anticoagulation and Medical Therapy

  2011cites this paper
• Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model.

  2011cites this paper
• Reduction of Myocardial Infarct Size by Dronedarone in Pigs—A Pleiotropic Action?

  2011cites this paper